The Ventura Heart Institute has moved (August, 2021) the clinical consultation office to a medical office building in Thousand Oaks.  We continue with our cardiovascular disease management programs, preventive cardiology consultation, non-invasive assessment tools to assess and manage cardiovascular disease.  Although the COVID-19 pandemic has significantly impacted healthcare delivery worldwide, Dr. Loh's prior consulting work in telemedicine has allowed patients to seamlessly continue care by remote mechanisms only requiring a smart device or computer with ability to receive email.  It is probable that telemedicine will be continued to be used if the patients choose after this health crisis because of its enhanced safety and convenience.  Patients can assess their risk of COVID-19 by using the link below that was created by Infermedica, an artificial intelligence company in healthcare co-founded by Dr. Loh and for which he serves as its Chief Medical Officer.

The guiding principle of the Ventura Heart Institute since it began operation in the 1980s has been that the best treatment of cardiovascular disease is its prevention. The emphasis has always been on wellness and prevention with the ideal care being proactive, rather than reactive, assessment and intervention.  The evolving healthcare landscape is increasing the emphasis on prevention, wellness, and value-based care utilizing evidence-based strategies for the optimal and cost effective assessment and management of cardiovascular risks.  Indeed, we believe that lifestyle modifications with proper nutrition, weight management, exercise and judicious use of appropriate medications used to expert-guided standards provide patients the greatest probability of a good outcome. 

That philosophy was manifested by VHI's dedication to extensive clinical research in the belief that engagement in research work improves clinical care.  Dr. Loh has been a principal investigator in over 160 phase 1, 2, and 3 clinical trials in new and novel cardiovascular therapies, with the goal of contributing to the improved care of patients everywhere.  He began his research career at the National Heart, Lung and Blood Institute at the National Institutes of Health near Washington DC in both the intramural (Molecular Diseases/Lipid Metabolism Branch) and extramural (Cardiac Diseases Branch; Division of Heart and Vascular Diseases) divisions.  He subsequently was a fellow in cardiology at Cedar-Sinai Medical Center and was appointed faculty in both the Department of Cardiology with Dr. HJC Swan and the Department of Thoracic and Cardiac Surgery with Dr. Jack Matloff.

Although VHI no longer provides public cardiovascular screenings for risk assessment, education programs or clinical research protocols, Dr. Loh continues, as he has since 2000, to write a monthly healthcare related newspaper colum entitled Second Opinion for the Ventura County Star, a USA Today affiliated newspaper. You may access Dr. Loh's prior Second Opinion newspaper columns and editorials by clicking on the link at https://www.vcstar.com and searching "Irving Loh". A summary of Dr. Loh's professional background is available by clicking the tab at the top of this page (Dr. Loh & the VHI Staff) or by going to his LinkedIn summary. He continues to lecture regionally and nationally on cardiovascular disease management and care coordination with focus on complex lipid abnormalities, heart failure, telemedicine, and artificial intelligence in healthcare (see below).  You may contact Dr. Loh by e-mail by clicking here.

He is Co-founder and Chief Medical Officer of Infermedica, an agile and innovative healthcare information technology company that is applying proprietary artificial intelligence and machine learning technologies to improve clinical decision support and empower patients to take control of self-assessment.  Infermedica created one of the world's most utilized COVID-19 RISK ASSESSMENT TOOL which is available by clicking the colored link.

He recently chaired the Technology and Innovation Committee of the California Chapter of the American College of Cardiology, and organized and moderated the "Colloquium on Artificial Intelligence, Technology, Innovation, and the Future of Cardiology" at UC San Francisco in October 2019 with faculty from Stanford, Google, UCSF, Scripps, Cedars-Sinai, and leading health technology firms from the Silicon Valley.  He was given the Outstanding Achievement Award 2019 from the CA ACC for this acknowleged nation leading program.  He remains on the Board of Directors for the California Chapter of the American College of Cardiology.   He is a member of two AI4H (Artificial Intelligence for Health) Working Groups for the use of AI in symptom assessment and its clinical evaluation, for the International Telecommunication Union of the World Health Organization/United Nations.  In 2019, he was appointed Adjunct Lecturer in the Department of Medicine, Stanford University School of Medicine.  In August of 2020, he presented a lecture at the Fourth Annual Heart Disease in Diabetes Conference in New York City on "Artificial Intelligence in the Future Management of Cardiovascular Disease and Diabetes".  He has recently invited to join the steering committee of the Cardiology-Oncology Innovation Network to blend the best of clinical medicine, technology, and innovation to better assess and manage the cardiovascular complication of cancer therapeutics.  He has also been accepted as a member of the Global Panel of the MIT Technology Review.

In addition, he was invited to lecture on "Harnessing Health Care Information Technology at the Point-of-Care to Improve Quality and Outcome" at the University of California - Berkeley, co-sponsored by the Center for Information Technology Research in the Interest of Society (CITRIS) at www.citris-uc.org, and the School of Public Health.  His poster on healthcare information technology was also accepted for presentation at Harvard's Inaugural America China Health Summit in Boston in September 2011.  He also presented at a regional TEDx program (http://youtu.be/b51KhIy3cA0) on how medical advances are validated.

He is on the advisory boards of several healthcare technology companies focused on improving the quality and efficiency of healthcare using novel science, innovation and networks of clinical experts nationally and internationally.